(NASDAQ: BDSX) Biodesix's forecast annual revenue growth rate of 18.84% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.74%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.05%.
Biodesix's revenue in 2026 is $96,096,000.On average, 7 Wall Street analysts forecast BDSX's revenue for 2026 to be $1,144,291,256, with the lowest BDSX revenue forecast at $1,092,636,412, and the highest BDSX revenue forecast at $1,180,479,972. On average, 7 Wall Street analysts forecast BDSX's revenue for 2027 to be $1,368,398,475, with the lowest BDSX revenue forecast at $1,297,436,243, and the highest BDSX revenue forecast at $1,434,003,159.
In 2028, BDSX is forecast to generate $1,604,332,732 in revenue, with the lowest revenue forecast at $1,521,644,547 and the highest revenue forecast at $1,672,767,818.